Malignant mesotheliomas are aggressive neoplasms arising from mesothelial cells lining the body cavities. Malignant peritoneal mesothelioma (MPM) account for about one-third of the cases. Though the ovarian involvement may be seen in the background of a diffuse peritoneal involvement, the presentation of MPM as a primary ovarian mass is rare. Here we present such a case who underwent surgery but had residual progressive lesion. She received further chemotherapy resulting in a complete response and is disease free for almost a year.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/0973-1482.139382 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Randomized phase II study of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant/refractory high grade ovarian cancer (NCI trial).
Clin Cancer Res
January 2025
Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Purpose: Mesothelin (MSLN) is highly expressed in high grade serous/ endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody drug conjugate directed at MSLN antigen with a tubulin polymerization inhibitor. We assessed safety, activity and pharmacokinetics of the combination AR/bevacizumab (Bev) (ARB) versus weekly paclitaxel (wP)/Bev (PB) in patients with platinum resistant/refractory HGOC (prrHGOC).
View Article and Find Full Text PDFCausal role of ischemic heart disease in ovarian cancer subtypes.
Discov Oncol
January 2025
Department of Cardiovascular Medicine, Jiu Jiang NO.1 People's Hospital, Jiujiang, 332000, China.
Background: Ischemic heart disease (IHD) may share biological mechanisms with cancer, including ovarian cancer, through pathways such as chronic inflammation and oxidative stress. However, the relationship between IHD and ovarian cancer subtypes remains unclear. This study used Mendelian randomization (MR) to explore potential causal associations.
View Article and Find Full Text PDFThe emergence of DNAM-1 as the facilitator of NK cell-mediated killing in ovarian cancer.
Front Immunol
January 2025
Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
Introduction: Ovarian cancer (OC) is the sixth most common malignancy in women and the poor 5-year survival emphasises the need for novel therapies. NK cells play an important role in the control of malignant disease but the nature of tumour-infiltrating and peripheral NK cells in OC remains unclear.
Methods: Using flow cytometric analysis, we studied the phenotype and function of NK cells in blood, primary tumour and metastatic tissue in 80 women with OC.
Controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: study protocol for a randomised controlled trial.
BMJ Open
January 2025
Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
Introduction: Multimodal anticancer therapies greatly damage the fertility of breast cancer patients, which raises urgent demand for fertility preservation. The standard options for fertility preservation are oocyte and embryo cryopreservation; both require controlled ovarian hyperstimulation (COH). However, there are safety concerns regarding breast cancer relapse due to the elevated serum estradiol levels during COH.
View Article and Find Full Text PDFComparison of ovarian reserve after laparoscopic cystectomy in patients with ovarian endometriosis differ in cyst size: A systematic review and meta-analysis.
Int J Gynaecol Obstet
January 2025
Reproductive Medicine Center, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Background: Whether cyst size affects ovarian reserve before and after surgery remains controversial.
Objective: The objective of this study is to determine whether cyst size causes differences in pre- and post-ovarian reserve impairment among patients with endometrioma.
Search Strategy: PubMed, Embase, Web of Science, Cochrane Library, and China National Knowledge Infrastructure were searched from inception to October 13, 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!